drug
as of 2026-07-01Roluperidone
Roluperidone 64 mgRoluperidone 32 mgMIN-101
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Minerva Neurosciences
4 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
4
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428Phase 3Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
NCT06107803Phase 1Completed
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
NCT03397134Phase 3Completed
Pharmacokinetic Study of MIN-101 in Healthy Subjects
NCT02232529Phase 1Completed
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Pui Leung, M.D
personKOL score —